REFERENCES
- Sport M. Collins physical activity and social exclusion. J Sports Sci 2004; 22: 727–740, [CSA]
- Cronin J, Sleivert G. Challenges in understanding the influence of maximal power training on improving athletic performance. Sports Med 2005; 35: 213–234, [INFOTRIEVE], [CROSSREF], [CSA]
- Verroken M. Drug use and abuse in sport. Baillieres Best Pract Res Clin Endocrinol Metab 2000; 14: 1–23, [INFOTRIEVE], [CROSSREF], [CSA]
- Gaudard A, Varlet-Marie E, Bressolle F, Audran M. Drugs for increasing oxygen and their potential use in doping: A review. Sports Med 2003; 33: 187–212, [INFOTRIEVE], [CROSSREF], [CSA]
- Rose A J, Richter E A. Skeletal muscle glucose uptake during exercise: How is it regulated?. Physiology (Bethesda) 2005; 20: 260–270, [CSA]
- Stirling J R, Zakynthinaki M S, Saltin B. A model of oxygen uptake kinetics in response to exercise: Including a means of calculating oxygen demand/deficit/debt. Bull Math Biol 2005; 67: 989–1015, [INFOTRIEVE], [CROSSREF], [CSA]
- Warburton D E, Gledhill N, Quinney H A. Blood volume, aerobic power, and endurance performance: Potential ergogenic effect of volume loading. Clin J Sport Med 2000; 10: 59–66, [INFOTRIEVE], [CROSSREF], [CSA]
- Sandler S G, Yu H, Rassai N. Risks of blood transfusion and their prevention. Clin Adv Hematol Oncol 2003; 1: 307–313, [INFOTRIEVE], [CSA]
- Ramsey G. Managing recalls and withdrawals of blood components. Transfus Med Rev 2004; 18: 36–45, [INFOTRIEVE], [CROSSREF], [CSA]
- Cobain T J. Fresh blood product manufacture, issue, and use: A chain of diminishing returns?. Transfus Med Rev 2004; 18: 279–292, [INFOTRIEVE], [CROSSREF], [CSA]
- Villar A, Jimenez-Yuste V, Quintana M, Hernandez-Navarro F. The use of haemostatic drugs in haemophilia: Desmopressin and antifibrinolytic agents. Haemophilia 2002; 8: 189–193, [INFOTRIEVE], [CROSSREF], [CSA]
- Bishton M, Chopra R. The role of granulocyte transfusions in neutropenic patients. Br J Haematol 2004; 127: 501–508, [INFOTRIEVE], [CROSSREF], [CSA]
- Beckman N, Nicholson G, Ashford M, Hambleton R. Blood pack fault monitoring. Vox Sang 2004; 87: 272–279, [INFOTRIEVE], [CROSSREF], [CSA]
- Goodnough L T. Autologous blood donation. Crit Care 2004; 8(Suppl 2)S49–S52, [INFOTRIEVE], [CROSSREF], [CSA]
- Pomper G J, Wu Y, Snyder E L. Risks of transfusion-transmitted infections: 2003. Curr Opin Hematol 2003; 10: 412–418, [INFOTRIEVE], [CROSSREF], [CSA]
- Pauli G. Tissue safety in view of CJD and variant CJD. Cell Tissue Bank 2005; 6: 191–200, [INFOTRIEVE], [CROSSREF], [CSA]
- Cervenakova L, Brown P. Advances in screening test development for transmissible spongiform encephalopathies. Expert Rev Anti Infect Ther 2004; 2: 873–880, [INFOTRIEVE], [CROSSREF], [CSA]
- Carson J L, Reynolds R C. In search of the transfusion threshold. Hematology 2005; 10(Suppl 1)86–88, [INFOTRIEVE], [CROSSREF], [CSA]
- Hardy J F. Current status of transfusion triggers for red blood cell concentrates. Transfus Apher Sci 2004; 31: 55–66, [INFOTRIEVE], [CROSSREF], [CSA]
- Pace N. The increase in hypoxia tolerance of normal men accompanying the polycythemia induced by transfusion of erythocytes. Am J Physiol 1947; 148: 152–163, [CSA]
- Audran M, Varlet-Marie E. Blood boosting today. Bull Acad Natl Med 2004; 188: 945–953, [INFOTRIEVE], [CSA]
- McArdle W D, Katch F I, Katch V L. Exercise Physiology. Energy, Nutrition, and Human Performance, 2nd Ed., W D McArdle, F I Katch, V L Katch. Lea and Febiger, Philadelphia 1986; 409–411
- Gledhill N. Blood doping and related issues: A brief review. Med Sci Sports Exerc 1982; 14: 183–189, [INFOTRIEVE], [CSA]
- Ghaphery N A. Performance-enhancing drugs. Orthop Clin North Am 1995; 26: 433–442, [INFOTRIEVE], [CSA]
- Smith D A, Perry P J. The efficacy of ergogenic agents in athletic competition. Part II: Other performance-enhancing agents. Ann Pharmacother 1992; 26: 653–659, [INFOTRIEVE], [CSA]
- Lippi G, Franchini M, Guidi G C. Haematological testing and antidoping policies. Int J Sports Med 2005; 26: 508–509, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nelson M, Ashenden M, Langshaw M, Popp H. Detection of homologous blood transfusion by flow cytometry: A deterrent against blood doping. Haematologica 2002; 87: 881–882, [INFOTRIEVE], [CSA]
- Nelson M, Popp H, Sharpe K, Ashenden M. Proof of homologous blood transfusion through quantification of blood group antigens. Haematologica 2003; 88: 1284–1295, [INFOTRIEVE], [CSA]
- Drexler C, Glock B, Vadon M, Staudacher E, Dauber E M, Ulrich S, Reisacher R B, Mayr W R, Lanzer G, Wagner T. Tetragametic chimerism detected in a healthy woman with mixed-field agglutination reactions in ABO blood grouping. Transfusion 2005; 45: 698–703, [INFOTRIEVE], [CROSSREF], [CSA]
- Malcovati L, Pascutto C, Cazzola M. Hematologic passport for athletes competing in endurance sports: A feasibility study. Haematologica 2003; 88: 570–571, [INFOTRIEVE], [CSA]
- Lee-Huang S. Cloning and expression of human erythropoietin cDNA in Escherichia coli. Proc Natl Acad Sci USA 1984; 81: 2708–2712, [INFOTRIEVE], [CROSSREF], [CSA]
- Franchini M, Gandini G, Lippi G, De Gironcoli M, Cantini M, Aprili G. Clinical use of erythropoietin. Recenti Prog Med 2004; 95: 129–136, [INFOTRIEVE], [CSA]
- Cazzola M. Further concerns about the medical risks of blood doping. Haematologica 2002; 87: 232, [INFOTRIEVE], [CSA]
- Joyner M J. VO2MAX, blood doping, and erythropoietin. Br J Sports Med 2003; 37: 190–191, [INFOTRIEVE], [CROSSREF], [CSA]
- Wilber R L. Detection of DNA-recombinant human epoetin-alfa as a pharmacological ergogenic aid. Sports Med 2002; 32: 125–142, [INFOTRIEVE], [CROSSREF], [CSA]
- Carnot P, Deflandre C. Sur l'activité hémopoïétique du serum au cours de la régénération du sang. CR Acad Sci Paris 1906; 143: 432–435, [CSA]
- Krumdieck N. Erythropoietic substance in the serum of anemic animals. Proc Soc Exp Biol Med 1943; 54: 14–17, [CSA]
- Ebert B L, Bunn H F. Regulation of the erythropoietin gene. Blood 1999; 94: 1864–1877, [INFOTRIEVE], [CSA]
- Lacombe C, Mayeux P. Biology of erythropoietin. Haematologica 1998; 83: 724–732, [INFOTRIEVE], [CSA]
- Krantz S B. Erythropoietin. Blood 1991; 77: 419–434, [INFOTRIEVE], [CSA]
- Choi D, Kim M, Park J. Erythropoietin: Physico- and biochemical analysis. J Chromatog B Biomed Appl 1996; 687: 189–199, [CROSSREF], [CSA]
- Bazan J F. A novel family of growth factor receptors: A common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor β chain. Biochem Biophys Res Commun 1989; 164: 788–792, [INFOTRIEVE], [CROSSREF], [CSA]
- Wen D, Boissel J P, Tracy T E, Gruninger R H, Mulcahy L S, Czelusniak J, Goodman M, Bunn H F. Erythropoietin structure-function relationships: High degree of sequence homology among mammals. Blood 1993; 82: 1507–1516, [INFOTRIEVE], [CSA]
- Maxwell P H, Ferguson D J, Osmond M K, Pugh C W, Heryet A, Doe B G, Johnson M H, Ratcliffe P J. Expression of a homologously recombined erythopoietin-SV40 T antigen fusion gene in mouse liver: Evidence for erythropoietin production by Ito cells. Blood 1994; 84: 1823–1830, [INFOTRIEVE], [CSA]
- Maxwell P H, Osmond M K, Pugh C W, Heryet A, Nicholls L G, Tan C C, Doe B G, Ferguson D J, Johnson M H, Ratcliffe P J. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 1993; 44: 1149–1162, [INFOTRIEVE], [CSA]
- Schmit R M, Bruyns E, Snodgrass H. Haematopoietic development of embryonic stem cells in vitro; cytokine and receptor gene expression. Genes Dev 1991; 5: 728–740, [CSA]
- Yasuda Y, Nagao M, Okano M, Masuda S, Sasaki R, Konishi H, Tanimura T. Localization of erythropoietin and erythropoietin-receptor in postimplantation mouse embryos. Dev Growth Differ 1993; 35: 711–722, [CROSSREF], [CSA]
- Marti H H, Wenger R H, Rivas L A, Straumann U, Digicaylioglu M, Henn V, Yonekawa Y, Bauer C, Gassmann M. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996; 8: 666–676, [INFOTRIEVE], [CROSSREF], [CSA]
- Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 1998; 273: 25381–25387, [INFOTRIEVE], [CROSSREF], [CSA]
- Yasuda Y, Fujita Y, Musha T, Tanaka H, Shiokawa S, Nakamatsu K, Mori S, Matsuo T, Nakamura Y. Expression of erythropoietin in human female reproductive organs. Ital J Anat Embryol 2001; 106(2)215–222, Suppl 2[INFOTRIEVE], [CSA]
- Fandrey J, Bunn H F. In vivo and in vitro regulation of erythropoietin mRNA: Measurement by competitive polymerase chain reaction. Blood 1993; 81: 617–623, [INFOTRIEVE], [CSA]
- Varlet-Marie E, Gaudard A, Audran M, Bressolle F. Pharmacokinetics/pharmacodynamics of recombinant human erythropoietins in doping control. Sports Med 2003; 33: 301–315, [INFOTRIEVE], [CSA]
- Varlet-Marie E, Gaudard A, Audran M, Gomeni R, Bressolle F. Pharmacokinetic-pharmacodynamic modelling of recombinant human erythropoietin in athletes. Int J Sports Med 2003; 24: 252–257, [INFOTRIEVE], [CSA]
- Parisotto R, Gore C J, Emslie K R, Ashenden M J, Brugnara C, Howe C, Martin D T, Trout G J, Hahn A G. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. Haematologica 2000; 85: 564–572, [INFOTRIEVE], [CSA]
- Connes P, Perrey S, Varray A, Prefaut C, Caillaud C. Faster oxygen uptake kinetics at the onset of submaximal cycling exercise following 4 weeks recombinant human erythropoietin (r-HuEPO) treatment. Pflugers Arch 2003; 447: 231–238, [INFOTRIEVE], [CROSSREF], [CSA]
- Storring P L, Tiplady R J, Gaines Das R E, Stenning B E, Lamikanra A, Rafferty B, Lee J. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998; 100: 79–89, [INFOTRIEVE], [CROSSREF], [CSA]
- Deicher R, Hörl W H. Differentiating factors between erythropoiesis-stimulating agents: A guide to selection for anaemia of chronic kidney disease. Drugs 2004; 64: 499–509, [INFOTRIEVE], [CROSSREF], [CSA]
- Elliott S, Egrie J, Browne J, Lorenzini T, Busse L, Rogers N, Ponting I. Control of rHuEPO biological activity: The role of carbohydrate. Exp Hematol 2004; 32: 1146–1155, [INFOTRIEVE], [CROSSREF], [CSA]
- MacDougall I C. Novel erythropoiesis stimulating protein. Semin Nephrol 2000; 20: 375–381, [INFOTRIEVE], [CSA]
- Fisher J W. Erythropoietin: Physiology and pharmacology update. Minireview. Exp Biol Med 2003; 228: 1–14, [CSA]
- Macdougall I C, Gray S J, Elston O, Breen C, Jenkins B, Browne J, Egrie J. Pharmacokinetics of novel erythropoieis protein compared with epoetin-alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392–2395, [INFOTRIEVE], [CSA]
- Macdougall I C. CERA (Continuous Erythropoietin Receptor Activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005; 4: 436–440, [INFOTRIEVE], [CSA]
- Cases A. Update in nephrology. Highlights from the 36th Annual Meeting of the American Society of Nephrology. Drugs Today (Barc) 2004; 40: 81–92, [CROSSREF], [CSA]
- Lippi G, Guidi G C. Gene manipulation and improvement of athletic performances: New strategies in blood doping. Br J Sports Med 2004; 38: 641, [INFOTRIEVE], [CROSSREF], [CSA]
- Fandrey J. Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol 2004; 286: R977–R988, [INFOTRIEVE], [CSA]
- López-Barneo J, Pardal R, Ortega-Sáenz P. Cellular mechanisms of oxygen sensing. Annu Rev Physiol 2001; 63: 259–287, [CROSSREF], [CSA]
- López-Barneo J. Oxygen-sensitive ion channels: How ubiquitous are they?. Trends Neurosci 1994; 17: 133–135, [CROSSREF], [CSA]
- Buckler K J. A novel oxygen-sensitive potassium current in rat carotid body type I cells. J Physiol 1997; 498: 649–662, [INFOTRIEVE], [CSA]
- Rychkov G Y, Adams M B, McMillen I C, Roberts M L. Oxygen-sensing mechanisms are present in the chromaffin cells of the sheep adrenal medulla before birth. J Physiol 1998; 509: 887–893, [INFOTRIEVE], [CROSSREF], [CSA]
- Youngson C, Nurse C, Yeger H, Cutz E. Oxygen sensing in airway chemoreceptors. Nature 1993; 365: 153–155, [INFOTRIEVE], [CROSSREF], [CSA]
- López-Barneo J. Oxygen and glucose sensing by carotid body glomus cells. Curr Opin Neurobiol 2003; 13: 493–499, [CROSSREF], [CSA]
- Semenza G L, Wang G L. A nuclear factor induced by hypoxia via de novo protein synthesis bind to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12: 5447–5454, [INFOTRIEVE], [CSA]
- Wang G L, Semenza G L. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270: 1230–1237, [INFOTRIEVE], [CROSSREF], [CSA]
- Marx J. How cells endure low oxygen. Science 2004; 303: 1454–1456, [INFOTRIEVE], [CROSSREF], [CSA]
- Vanrenterghem Y, Vanwalleghem J. Benefits and concerns of treating pre-dialysis and renal transplant patients with recombinant human erythropoietin. Nephrol Dial Transplant 1998; 13(Suppl 2)13–15, [INFOTRIEVE], [CROSSREF], [CSA]
- Lage J M, Panizo C, Masdeu J, Rocha E. Cyclist's doping associated with cerebral sinus thrombosis. Neurology 2002; 58: 665, [INFOTRIEVE], [CSA]
- Rosenzweig M Q, Bender C M, Lucke J P, Yasko J M, Brufsky A M. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage 2004; 27: 185–190, [INFOTRIEVE], [CROSSREF], [CSA]
- Delanty N, Vaughan C, Frucht S, Stubgen P. Erythropoietin-associated hypertensive posterior leukoencephalopathy. Neurology 1997; 49: 686–689, [PUBMED], [INFOTRIEVE], [CSA]
- Beccari M. Seizures in dialysis patients treated with recombinant erythropoietin. Review of the literature and guidelines for prevention. Int J Artif Organs 1994; 17: 5–13, [INFOTRIEVE], [CSA]
- Goodnough L T, Price T H, Friedman K D, Johnston M, Ciavarella D, Khan N, Sacher R, Vogler W R, Wissel M, Abels R I. A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: Dose, response, toxicity, and efficacy. Transfusion 1994; 34: 66–71, [INFOTRIEVE], [CROSSREF], [CSA]
- Bennett C L, Luminari S, Nissenson A R, Tallman M S, Klinge S A, McWilliams N, McKoy J M, Kim B, Lyons E A, Trifilio S M, Raisch D W, Evens A M, Kuzel T M, Schumock G T, Belknap S M, Locatelli F, Rossert J, Casadevall N. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004; 351: 1403–1408, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lim L C. Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure. Hematology 2005; 10: 255–259, [INFOTRIEVE], [CROSSREF], [CSA]
- Casadevall N, Cournoyer D, Marsh J, Messner H, Pallister C, Parker-Williams J, Rossert J. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol 2004; 73: 389–396, [INFOTRIEVE], [CROSSREF], [CSA]
- Piron M, Loo M, Gothot A, Tassin F, Fillet G, Beguin Y. Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia. Blood 2001; 97: 442–448, [INFOTRIEVE], [CROSSREF], [CSA]
- Juul S E, Yachnis A T, Christensen R D. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 1998; 52: 235–249, [INFOTRIEVE], [CROSSREF], [CSA]
- Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, Onozaki M, Hashimoto M, Musha T, Ogawa K, Fujita H, Nakamura Y, Shiozaki H, Utsumi H. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003; 24: 1021–1029, [INFOTRIEVE], [CROSSREF], [CSA]
- Broudy V C, Lin N, Brice M, Nakamoto B, Papayannopoulou T. Erythropoietin receptor characteristics on primary human erythroid cells. Blood 1991; 77: 2583–2590, [INFOTRIEVE], [CSA]
- Lippi G, Guidi G. Laboratory screening for erythropoietin abuse in sport: An emerging challenge. Clin Chem Lab Med 2000; 38: 13–19, [INFOTRIEVE], [CROSSREF], [CSA]
- Gareau R, Audran M, Baynes R D, Flowers C H, Duvallet A, Senecal L, Brisson G R. Erythropoietin abuse in athletes. Nature 1996; 380: 113, [INFOTRIEVE], [CROSSREF], [CSA]
- Lippi G, Manzato F, Franchini M, Guidi G. Relationship between hematocrit, primary hemostasis, and cardiovascular disease in athletes. Am Heart J 2002; 144: E14, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kazlauskas R, Howe C, Trout G. Strategies for rhEPO detection in sport. Clin J Sport Med 2002; 12: 229–235, [INFOTRIEVE], [CROSSREF], [CSA]
- Sharpe K, Hopkins W, Emslie K R, Howe C, Trout G J, Kazlauskas R, Ashenden M J, Gore C J, Parisotto R, Hahn A G. Development of reference ranges in elite athletes for markers of altered erythropoiesis. Haematologica 2002; 87: 1248–1257, [INFOTRIEVE], [CSA]
- Lippi G, Franchini M, Guidi G. Second generation blood tests to detect erythropoietin abuse by athletes: Effective but not preventive?. Haematologica 2004; 89: ELT05, [INFOTRIEVE], [CSA]
- Robinson N, Saugy M, Mangin P. Effects of exercise on the secondary blood markers commonly used to suspect erythropoietin doping. Clin Lab 2003; 49: 57–62, [INFOTRIEVE], [CSA]
- Ashenden M J, Gore C J, Parisotto R, Sharpe K, Hopkins W G, Hahn A G. Effect of altitude on second-generation blood tests to detect erythropoietin abuse by athletes. Haematologica 2003; 88: 1053–1062, [INFOTRIEVE], [CSA]
- Lippi G, Salvagno G L, Brocco G, Guidi G C. Preanalytical variability in laboratory testing: Influence of the blood drawing technique. Clin Chem Lab Med 2005; 43: 319–325, [INFOTRIEVE], [CROSSREF], [CSA]
- Lippi G, Salvagno G L, Solero G P, Franchini M, Guidi G C. Stability of blood cell counts, hematologic parameters and reticulocytes indexes on the Advia A120 hematologic analyzer. J Lab Clin Med 2005; 146: 333–340, [INFOTRIEVE], [CROSSREF], [CSA]
- Villarrubia J. Decision rules for hematology review. An international perspective. Lab Hematol 2004; 10: 158–159, [INFOTRIEVE], [CSA]
- Breidbach A, Catlin D H, Green G A, Tregub I, Truong H, Gorzek J. Detection of recombinant human erythropoietin in urine by isoelectric focusing. Clin Chem 2003; 49: 901–907, [INFOTRIEVE], [CROSSREF], [CSA]
- Wide L, Bengtsson C, Berglund B, Ekblom B. Detection in blood and urine of recombinant erythropoietin administered to healthy men. Med Sci Sports Exerc 1995; 27: 1569–1576, [INFOTRIEVE], [CSA]
- Catlin D H, Breidbach A, Elliott S, Glaspy J. Comparison of isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. Clin Chem 2002; 48: 2057–2059, [INFOTRIEVE], [CSA]
- Lasne F, Martin L, Crepin N, de Ceaurriz J. Detection of isoelectric profiles of erythropoietin in urine: Differentiation of natural and administered recombinant hormones. Anal Biochem 2002; 311: 119–126, [INFOTRIEVE], [CROSSREF], [CSA]
- Lopez-Soto-Yarritu P, Diez-Masa J C, Cifuentes A, de Frutos M. Improved capillary isoelectric focusing method for recombinant erythropoietin analysis. J Chromatogr A 2002; 968: 221–228, [INFOTRIEVE], [CSA]
- Varlet-Marie E, Audran M, Lejeune M, Bonafoux B, Sicart M T, Marti J, Piquemal D, Commes T. Analysis of human reticulocyte genes reveals altered erythropoiesis: Potential use to detect recombinant human erythropoietin doping. Haematologica 2004; 89: 991–997, [INFOTRIEVE], [CSA]
- Brugnara C. Reticulocyte cellular indices: A new approach in the diagnosis of anemias and monitoring of erythropoietic function. Crit Rev Clin Lab Sci 2000; 37: 93–130, [INFOTRIEVE], [CROSSREF], [CSA]
- Wide L, Wikstrom B, Eriksson K. A new principle suggested for detection of darbepoetin-alpha (NESP) doping. Ups J Med Sci 2003; 108: 229–238, [INFOTRIEVE], [CSA]
- Rusko H K, Tikkanen H O, Peltonen J E. Altitude and endurance training. J Sports Sci 2004; 22: 928–944, [INFOTRIEVE], [CROSSREF], [CSA]
- Wu T, Li S, Ward M P. Tibetans at extreme altitude. Wilderness Environ Med 2005; 16: 47–54, [INFOTRIEVE], [CSA]
- Ge R L, Witkowski S, Zhang Y, Alfrey C, Sivieri M, Karlsen T, Resaland G K, Harber M, Stray-Gundersen J, Levine B D. Determinants of erythropoietin release in response to short-term hypobaric hypoxia. J Appl Physiol 2002; 92: 2361–2367, [INFOTRIEVE], [CSA]
- Gore C J, Hahn A G, Burge C M, Telford R D. VO2max and haemoglobin mass of trained athletes during high intensity training. Int J Sports Med 1997; 18: 477–482, [INFOTRIEVE], [CSA]
- Coote J H. Medicine and mechanisms in altitude sickness: Recommendations. Sports Med 1995; 20: 148–159, [INFOTRIEVE], [CSA]
- Fandrey J. High-altitude polycythemia. Haematologica 2005; 90: 1, [INFOTRIEVE], [CSA]
- Leon-Velarde F, Maggiorini M, Reeves J T, Aldashev A, Asmus I, Bernardi L, Ge R L, Hackett P, Kobayashi T, Moore L G, Penaloza D, Richalet J P, Roach R, Wu T, Vargas E, Zubieta-Castillo G, Zubieta-Calleja G. Consensus statement on chronic and subacute high altitude diseases. High Alt Med Biol 2005; 6: 147–157, [INFOTRIEVE], [CROSSREF], [CSA]
- Chapman R F, Stray-Gundersen J, Levine B D. Individual variation in response to altitude training. J Appl Physiol 1998; 85: 1448–1456, [INFOTRIEVE], [CSA]
- Alfrey C P, Rice L, Udden M M, Driscoll T B. Neocytolysis: Physiological down-regulator of red-cell mass. Lancet 1997; 349: 1389–1390, [INFOTRIEVE], [CROSSREF], [CSA]
- Rice L, Alfrey C P. The negative regulation of red cell mass by neocytolysis: Physiologic and pathophysiologic manifestations. Cell Physiol Biochem 2005; 15: 245–250, [INFOTRIEVE], [CROSSREF], [CSA]
- Rice L, Ruiz W, Driscoll T, Whitley C E, Tapia R, Hachey D L, Gonzales G F, Alfrey C P. Neocytolysis on descent from altitude: A newly recognized mechanism for the control of red cell mass. Ann Intern Med 2001; 134: 652–656, [PUBMED], [INFOTRIEVE], [CSA]
- Harris B A, Jr, Epstein P E. Out of thin air: The evolving enigma of erythropoietin and neocytolysis. Ann Intern Med 2001; 134: 710–712, [PUBMED], [INFOTRIEVE], [CSA]
- Rice L, Alfrey C P. Down-regulation of red cell mass by neocytolysis in space and on Earth. Eur J Physiol 2000; 441: R91–R94, [CSA]
- Trial J, Rice L. Erythropoietin withdrawal leads to the destruction of young red cells at the endothelial-macrophage interface. Curr Pharm Des 2004; 10: 183–190, [INFOTRIEVE], [CROSSREF], [CSA]
- Testa U. Apoptotic mechanisms in the control of erythropoiesis. Leukemia 2004; 18: 1176–1199, [INFOTRIEVE], [CROSSREF], [CSA]
- Dick F W. Training at altitude in practice. Int J Sports Med 1992; 13(Suppl 1)S203–S206, [INFOTRIEVE], [CSA]
- Hahn A G, Gore C J. The effect of altitude on cycling performance: A challenge to traditional concepts. Sports Med 2001; 31: 533–557, [INFOTRIEVE], [CROSSREF], [CSA]
- Mairbaurl H, Schobersberger W, Humpeler E, Hasibeder E, Fischer W, Raas E. Beneficial effects of exercising at moderate altitude on oxygen transport and on exercise performance. Pflügers Arch 1986; 406: 594–599, [CROSSREF], [CSA]
- Bigard A X, Brunet A, Guezennec C Y, Monod H. Skeletal muscle changes after endurance training at high altitude. J Appl Physiol 1991; 71: 2114–2121, [INFOTRIEVE], [CSA]
- Eckardt K, Boutellier U, Kurtz A, Schopen M, Koller E, Bauer C. Rate of erythropoietin formation in humans in response to acute hypobaric hypoxia. J Appl Physiol 1989; 66: 1785–1788, [INFOTRIEVE], [CSA]
- Levine B D, Stray-Gundersen J. “Living high-training low”: Effect of moderate-altitude acclimatization with low-altitude training on performance. J Appl Physiol 1997; 83: 102–112, [INFOTRIEVE], [CSA]
- Morton J P, Cable N T. The effects of intermittent hypoxic training on aerobic and anaerobic performance. Ergonomics 2005; 48: 1535–1546, [INFOTRIEVE], [CROSSREF], [CSA]
- Levine B D, Stray-Gundersen J. A practical approach to altitude training: Where to live and train for optimal performance enhancement. Int J Sports Med 1992; 13(Suppl 1)S209–S212, [INFOTRIEVE], [CSA]
- Stray-Gundersen J, Chapman R F, Levine B D. “Living high-training low” altitude training improves sea level performance in male and female elite runners. J Appl Physiol 2001; 91: 1113–1120, [INFOTRIEVE], [CSA]
- Scoggin C H, Doekel R D, Kruger M H, Zwillich C W, Weil J V. Familial aspects of decreased hypoxic drive in endurance athletes. J Appl Physiol 1978; 44: 464–468, [INFOTRIEVE], [CSA]
- Wang G L, Jiang B H, Rue E A, Semenza G L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510–5514, [INFOTRIEVE], [CROSSREF], [CSA]
- Murray T H. An Olympic tail?. Nat Rev Genet 2003; 4: 494, [INFOTRIEVE], [CROSSREF], [CSA]
- Lippi G, Solero G P, Guidi G. Athletes genotyping: Ethical and legal issues. Int J Sports Med 2004; 25: 159, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Schmidt W. Effects of intermittent exposure to high altitude on blood volume and erythropoietic activity. High Alt Med Biol 2002; 3: 167–176, [INFOTRIEVE], [CROSSREF], [CSA]
- Julian C G, Gore C J, Wilber R L, Daniels J T, Fredericson M, Stray-Gundersen J, Hahn A G, Parisotto R, Levine B D. Intermittent normobaric hypoxia does not alter performance or erythropoietic markers in highly trained distance runners. J Appl Physiol 2004; 96: 1800–1807, [INFOTRIEVE], [CROSSREF], [CSA]
- Rodríguez F A. Intermittent hypoxia: An alternative to acclimatization to high altitude and enhancement of athletic performance?. Am J Med Sports 2002; 4: 385–391, [CSA]
- Rodriguez F A, Ventura J L, Casas M, Casas H, Pages T, Rama R, Ricart A, Palacios L, Viscor G. Erythropoietin acute reaction and haematological adaptations to short, intermittent hypobaric hypoxia. Eur J Appl Physiol 2000; 82: 170–177, [INFOTRIEVE], [CROSSREF], [CSA]
- Abellán R, Remacha A F, Ventura R, Sardà M P, Segura J, Rodríguez F A. Hematologic response to four weeks of intermittent hypobaric hypoxia in highly trained athletes. Haematologica 2005; 90: 126–127, [CSA]
- Roels B, Millet G P, Marcoux C J, Coste O, Bentley D J, Candau R B. Effects of hypoxic interval training on cycling performance. Med Sci Sports Exerc 2005; 37: 138–146, [INFOTRIEVE], [CROSSREF], [CSA]
- Lundby C, Nielsen T K, Dela F, Damsgaard R. The influence of intermittent altitude exposure to 4100 m on exercise capacity and blood variables. Scand J Med Sci Sports 2005; 15: 182–187, [INFOTRIEVE], [CROSSREF], [CSA]
- Serebrovskaya T V. Intermittent hypoxia research in the former Soviet Union and the Commonwealth of Independent States: History and review of the concept and selected applications. High Alt Med Biol 2002; 3: 205–221, [INFOTRIEVE], [CROSSREF], [CSA]
- Levine B D. Intermittent hypoxic training: Fact and fancy. High Alt Med Biol 2002; 3: 177–193, [INFOTRIEVE], [CROSSREF], [CSA]
- Wilber R L. Current trends in altitude training. Sports Med 2001; 31: 249–265, [INFOTRIEVE], [CROSSREF], [CSA]
- Koistinen P O, Rusko H, Irjala K, Rajamaki A, Penttinen K, Sarparanta V P, Karpakka J, Leppaluoto J. EPO, red cells, and serum transferrin receptor in continuous and intermittent hypoxia. Med Sci Sports Exerc 2000; 32: 800–804, [INFOTRIEVE], [CROSSREF], [CSA]
- Benoit H, Germain M, Barthelemy J C, Denis C, Castells J, Dormois D, Lacour J R, Geyssant A. Pre-acclimatization to high altitude using exercise with normobaric hypoxic gas mixtures. Int J Sports Med 1992; 13(Suppl 1)S213–S216, [INFOTRIEVE], [CSA]
- Bernardi L. Interval hypoxic training. Adv Exp Med Biol 2001; 502: 377–399, [INFOTRIEVE], [CSA]
- Ashenden M J, Hahn A G, Martin D T, Logan P, Parisotto R, Gore C J. A comparison of the physiological response to simulated altitude exposure and r-HuEpo administration. J Sports Sci 2001; 19: 831–837, [INFOTRIEVE], [CROSSREF], [CSA]
- Bahrke M S, Shukitt-Hale B. Effects of altitude on mood, behaviour and cognitive functioning: A review. Sports Med 1993; 16: 97–125, [INFOTRIEVE], [CSA]
- American College of Physicians. Practice strategies for elective red blood cell transfusions. Ann Intern Med 1992; 116: 403–406, [CSA]
- Scott M G, Kucik D F, Goodnough L T, Monk T G. Blood substitutes: Evolution and future applications. Clin Chem 1997; 43: 1724–1731, [INFOTRIEVE], [CSA]
- Ma Z, Monk T G, Goodnough L T, McClellan A, Gawryl M, Clark T, Moreira P, Keipert P E, Scott M G. Effect of hemoglobin- and Perflubron-based oxygen carriers on common clinical laboratory tests. Clin Chem 1997; 43: 1732–1737, [INFOTRIEVE], [CSA]
- Goodnough L T, Scott M G, Monk T G. Oxygen carriers as blood substitutes. Past, present, and future. Clin Orthop Relat Res 1998; 357: 89–100, [INFOTRIEVE], [CROSSREF], [CSA]
- Stowell C P. What happened to blood substitutes?. Transfus Clin Biol 2005; 12: 374–379, [INFOTRIEVE], [CSA]
- Klein H G. Blood substitutes: How close to a solution?. Dev Biol (Basel) 2005; 120: 45–52, [CSA]
- Keipert P E. Perfluorochemical emulsions: Future alternatives to transfusion. Blood Subst Princ Meth Prod Clin Trials 1998; 2: 127–156, [CSA]
- Wolfson M R, Shaffer T H. Pulmonary applications of perfluorochemical liquids: Ventilation and beyond. Paediatr Respir Rev 2005; 6: 117–127, [INFOTRIEVE], [CROSSREF], [CSA]
- Spahn D R. Blood substitutes. Artificial oxygen carriers: Perfluorocarbon emulsions. Crit Care 1999; 3: R93–R97, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Riess J G. Understanding the fundamentals of perfluorocarbons and perfluorocarbon emulsions relevant to in vivo oxygen delivery. Artif Cells Blood Substit Immobil Biotechnol 2005; 33: 47–63, [INFOTRIEVE], [CSA]
- Speit G, Dennog C, Radermacher P, Rothfuss A. Genotoxicity of hyperbaric oxygen. Mutat Res 2002; 512: 111–119, [INFOTRIEVE], [CROSSREF], [CSA]
- Patel S, Mehra A. Modeling of oxygen transport in blood-perfluorocarbon emulsion mixtures: Part II: Tissue oxygenation. ASAIO J 1998; 44: 157–165, [PUBMED], [INFOTRIEVE], [CSA]
- Spence R K. Perfluorocarbons in the twenty first century: Clinical applications as transfusion alternatives. Artif Cells Blood Substit Immobil Biotechnol 1995; 23: 367–380, [INFOTRIEVE], [CSA]
- Clark L C, Gollan F. Survival of mammals breathing liquids equilibrated with oxygen at atmospheric pressure. Science 1966; 152: 1755–1756, [INFOTRIEVE], [CSA]
- Hill S E. Oxygen therapeutics. Current concepts. Can J Anaesth 2001; 48(4 Suppl)S32–S40, [INFOTRIEVE], [CSA]
- Flaim S F, Hazard D R, Hogan J, Peters R M. Characterization and mechanism of side-effects of Oxygent HT (highly concentrated fluorocarbon emulsion) in swine. Artif Cells Blood Substit Immobil Biotechnol 1994; 22: 1511–1515, [INFOTRIEVE], [CSA]
- Noveck R J, Shannon E J, Leese P T, Shorr J S, Flaim K E, Keipert P E, Woods C M. Randomized safety studies of intravenous perflubron emulsion. II. Effects on immune function in healthy volunteers. Anesth Analg 2000; 91: 812–822, [INFOTRIEVE], [CROSSREF], [CSA]
- Fernandez R, Sarma V, Younkin E, Hirschl R B, Ward P A, Younger J G. Exposure to perflubron is associated with decreased Syk phosphorylation in human neutrophils. J Appl Physiol 2001; 91: 1941–1947, [INFOTRIEVE], [CSA]
- Smith D J, Lane T A. Effect of high concentration perflubron emulsion on platelet function. Biomater Artif Cells Immobilization Biotechnol 1993; 21: 173–181, [INFOTRIEVE], [CSA]
- Merz U, Klosterhalfen B, Kellinghaus M, Peschgens T, Pluschke S, Hoernchen H. Effects of single and multiple doses of perfluorocarbon in comparison with continuous partial liquid ventilation on gas exchange and lung pathology in newborn surfactant-depleted pigs. Crit Care Med 2001; 29: 645–651, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Audran M, Krafft M P, De Ceaurriz J, Maturin J C, Sicart M T, Marion B, Bougard G, Bressolle F. Determination of perfluorodecalin and perfluoro-N-methylcyclohexylpiperidine in rat blood by gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 2000; 745: 333–343, [INFOTRIEVE], [CROSSREF], [CSA]
- Shaffer T H, Foust R, 3rd, Wolfson M R, Miller T F, Jr. Analysis of perfluorochemical elimination from the respiratory system. J Appl Physiol 1997; 83: 1033–1040, [INFOTRIEVE], [CSA]
- Mazzoni M, Nugent L, Klein D, Hoffman J, Sekins K M, Flaim S F. Dose monitoring in partial liquid ventilation by infrared measurement of expired perfluorochemicals. Biomed Instrum Technol 1999; 33: 356–364, [INFOTRIEVE], [CSA]
- Proquitte H, Rudiger M, Wauer R R, Schmalisch G. Breathing gas perfluorocarbon measurements using an absorber filled with zeolites. Br J Anaesth 2003; 91: 736–738, [INFOTRIEVE], [CROSSREF], [CSA]
- Schumacher Y O, Ashenden M. Doping with artificial oxygen carriers: An update. Sports Med 2004; 34: 141–150, [INFOTRIEVE], [CROSSREF], [CSA]
- Spahn D R, Kocian R. Artificial O2 carriers: Status in 2005. Curr Pharm Des 2005; 11: 4099–4114, [INFOTRIEVE], [CROSSREF], [CSA]
- Chang T M. Oxygen carriers. Curr Opin Investig Drugs 2002; 3: 1187–1190, [INFOTRIEVE], [CSA]
- Eike J H, Palmer A F. Oxidized mono-, di-, tri-, and polysaccharides as potential hemoglobin cross-linking reagents for the synthesis of high oxygen affinity artificial blood substitutes. Biotechnol Prog 2004; 20: 953–962, [INFOTRIEVE], [CROSSREF], [CSA]
- Bobofchak K M, Mito T, Texel S J, Bellelli A, Nemoto M, Traystman R J, Koehler R C, Brinigar W S, Fronticelli C. A recombinant polymeric hemoglobin with conformational, functional, and physiological characteristics of an in vivo O2 transporter. Am J Physiol Heart Circ Physiol 2003; 285: H549–H561, [INFOTRIEVE], [CSA]
- Tsai C H, Ho C. Recombinant hemoglobins with low oxygen affinity and high cooperativity. Biophys Chem 2002; 98: 15–25, [INFOTRIEVE], [CROSSREF], [CSA]
- Lieberthal W, Fuhro R, Freedman J E, Toolan G, Loscalzo J, Valeri C R. O-raffinose cross-linking markedly reduces systemic and renal vasoconstrictor effects of unmodified human hemoglobin. J Pharmacol Exp Ther 1999; 288: 1278–1287, [INFOTRIEVE], [CSA]
- Talarico T L, Guise K J, Stacey C J. Chemical characterization of pyridoxalated hemoglobin polyoxyethylene conjugate. Biochim Biophys Acta 2000; 1476: 53–65, [INFOTRIEVE], [CSA]
- Kim H W, Greenburg A G. Artificial oxygen carriers as red blood cell substitutes: A selected review and current status. Artif Organs 2004; 28: 813–828, [INFOTRIEVE], [CROSSREF], [CSA]
- Moore E E, Johnson J L, Cheng A M, Masuno T, Banerjee A. Insights from studies of blood substitutes in trauma. Shock 2005; 24: 197–205, [INFOTRIEVE], [CROSSREF], [CSA]
- Hughes G S, Jr, Francome S F, Antal E J, Adams W J, Locker P K, Yancey E P, Jacobs E E, Jr. Hematologic effects of a novel hemoglobin-based oxygen carrier in normal male and female subjects. J Lab Clin Med 1995; 126: 444–451, [INFOTRIEVE], [CSA]
- Hughes G S, Jr, Antal E J, Locker P K, Francom S F, Adams W J, Jacobs E E, Jr. Physiology and pharmacokinetics of a novel hemoglobin-based oxygen carrier in humans. Crit Care Med 1996; 24: 756–764, [INFOTRIEVE], [CROSSREF], [CSA]
- Hughes G S, Jr, Yancey E P, Albrecht R, Locker P K, Francom S F, Orringer E P, Antal E J, Jacobs E E, Jr. Hemoglobin-based oxygen carrier preserves submaximal exercise capacity in humans. Clin Pharmacol Ther 1995; 58: 434–443, [INFOTRIEVE], [CROSSREF], [CSA]
- Resta T C, Walker B R, Eichinger M R, Doyle M P. Rate of NO scavenging alters effects of recombinant hemoglobin solutions on pulmonary vasoreactivity. J Appl Physiol 2002; 93: 1327–1336, [INFOTRIEVE], [CSA]
- Scatena R, Giardina B. O-raffinose-polymerised haemoglobin. A biochemical and pharmacological profile of an oxygen carrier. Expert Opin Biol Ther 2001; 1: 121–127, [INFOTRIEVE], [CROSSREF], [CSA]
- Goebel C, Alma C, Howe C, Kazlauskas R, Trout G. Methodologies for detection of hemoglobin-based oxygen carriers. J Chromatogr Sci 2005; 43: 39–46, [INFOTRIEVE], [CSA]
- Lasne F, Crepin N, Ashenden M, Audran M, de Ceaurriz J. Detection of hemoglobin-based oxygen carriers in human serum for doping analysis: Screening by electrophoresis. Clin Chem 2004; 50: 410–415, [INFOTRIEVE], [CROSSREF], [CSA]
- Guan F, Uboh C E, Soma L R, Luo Y, Jahr J S, Driessen B. Confirmation and quantification of hemoglobin-based oxygen carriers in equine and human plasma by hyphenated liquid chromatography tandem mass spectrometry. Anal Chem 2004; 76: 5127–5135, [INFOTRIEVE], [CROSSREF], [CSA]
- Varlet-Marie E, Ashenden M, Lasne F, Sicart M T, Marion B, de Ceaurriz J, Audran M. Detection of hemoglobin-based oxygen carriers in human serum for doping analysis: Confirmation by size-exclusion HPLC. Clin Chem 2004; 50: 723–731, [INFOTRIEVE], [CROSSREF], [CSA]
- Kenakin T. Allosteric modulators: The new generation of receptor antagonist. Mol Interv 2004; 4: 222–229, [INFOTRIEVE], [CROSSREF], [CSA]
- Randad R S, Mahran M A, Mehanna A S, Abraham D J. Allosteric modifiers of hemoglobin, I: Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents. J Med Chem 1991; 34: 752–757, [INFOTRIEVE], [CROSSREF], [CSA]
- Papassotiriou I, Kister J, Griffon N, Stamoulakatou A, Abraham D J, Marden M C, Loukopoulos D, Poyart C. Modulating the oxygen affinity of human fetal haemoglobin with synthetic allosteric modulators. Br J Haematol 1998; 102: 1165–1167, [INFOTRIEVE], [CROSSREF], [CSA]
- Abraham D J, Wireko F C, Randad R S, Poyart C, Kister J, Bohn B, Liard J F, Kunert M P. Allosteric modifiers of hemoglobin: 2-[4-[[(3,5-disubstituted anilino)carboxy]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats. Biochemistry 1992; 31: 9141–9149, [INFOTRIEVE], [CROSSREF], [CSA]
- Wahr J A, Gerber M, Venitz J, Baliga N. Allosteric modification of oxygen delivery by hemoglobin. Anesth Analg 2001; 92: 615–620, [INFOTRIEVE], [CROSSREF], [CSA]
- Steffen R P, Liard J F, Gerber M J, Hoffman S J. Allosteric modification of hemoglobin by RSR13 as a therapeutic strategy. Adv Exp Med Biol 2003; 530: 249–259, [INFOTRIEVE], [CSA]
- Hou H, Khan N, O'Hara J A, Grinberg O Y, Dunn J F, Abajian M A, Wilmot C M, Demidenko E, Lu S, Steffen R P, Swartz H M. Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys 2005; 61: 1503–1509, [INFOTRIEVE], [CROSSREF], [CSA]
- Youssef A M, Safo M K, Danso-Danquah R, Joshi G S, Kister J, Marden M C, Abraham D J. Synthesis and X-ray studies of chiral allosteric modifiers of hemoglobin. J Med Chem 2002; 45: 1184–1195, [INFOTRIEVE], [CROSSREF], [CSA]
- Lippi G, Franchini M. The new frontiers of blood doping. Recenti Prog Med 2002; 93: 1–8, [INFOTRIEVE], [CSA]
- Drugs R D 2005; 6: 178–185, [No authors listed]. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13[CROSSREF], [CSA]
- Paranka N. Hemoglobin modifiers: Is RSR13 the next aerobic enhancer?. Bloodline Rev 2001; 1: 23–24, [CSA]
- Breidbach A, Catlin D H. RSR13, a potential athletic performance enhancement agent: Detection in urine by gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom 2001; 15: 2379–2382, [INFOTRIEVE], [CROSSREF], [CSA]
- The world antidoping code. The 2005 Prohibited List International Standard. World Anti-Doping Agency 2005, http://www.wada-ama.org/rtecontent/document/list_2005.pdf. (Last accessed: May 28, 2006)
- Heeney M M, Andrews N C. Iron homeostasis and inherited iron overload disorders: An overview. Hematol Oncol Clin North Am 2004; 18: 1379–1403, [INFOTRIEVE], [CSA]
- Beard J, Tobin B. Iron status and exercise. Am J Clin Nutr 2000; 72(2 Suppl)594S–597S, [INFOTRIEVE], [CSA]
- Brugnara C, Colella G M, Cremins J, Langley R C, Jr, Schneider T J, Rutherford C J, Goldberg M A. Effects of subcutaneous recombinant human erythropoietin in normal subjects: Development of decreased reticulocyte hemoglobin content and iron deficient erythropoiesis. J Lab Clin Med 1994; 123: 660–667, [INFOTRIEVE], [CSA]
- Institute of Medicine. Food and Nutrition Board. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium and Zinc. National Academy Press, Washington, DC 2001, Available at http://darwin.nap.edu/books/0309072794/html/290.html
- Fallon K E. Utility of hematological and iron-related screening in elite athletes. Clin J Sport Med 2004; 14: 145–152, [INFOTRIEVE], [CROSSREF], [CSA]
- Fogelholm M. Inadequate iron status in athletes: An exaggerated problem?. Sports Nutrition: Minerals and Electrolytes, C V Kies, J A Driskell. CRC Press, Boca Raton 1995; 81–95
- Nielsen P, Nachtigall D. Iron supplementation in athletes. Current recommendations. Sports Med 1998; 26: 207–216, [INFOTRIEVE], [CROSSREF], [CSA]
- Deugnier Y, Loreal O, Carre F, Duvallet A, Zoulim F, Vinel J P, Paris J C, Blaison D, Moirand R, Turlin B, Gandon Y, David V, Megret A, Guinot M. Increased body iron stores in elite road cyclists. Med Sci Sports Exerc 2002; 34: 876–880, [INFOTRIEVE], [CROSSREF], [CSA]
- Zotter H, Robinson N, Zorzoli M, Schattenberg L, Saugy M, Mangin P. Abnormally high serum ferritin levels among professional road cyclists. Br J Sports Med 2004; 38: 704–708, [INFOTRIEVE], [CROSSREF], [CSA]
- Zoller H, Vogel W. Iron supplementation in athletes—first do no harm. Nutrition 2004; 20: 615–619, [INFOTRIEVE], [CROSSREF], [CSA]
- Lippi G, Schena F, Franchini M, Salvagno G L, Guidi G C. Serum ferritin as a marker of potential biochemical iron overload in athletes. Clin J Sport Med 2005; 15: 356–358, [INFOTRIEVE], [CROSSREF], [CSA]
- Besarab A, Frinak S, Yee J. An indistinct balance: The safety and efficacy of parenteral iron therapy. J Am Soc Nephrol 1999; 10: 2029–2043, [INFOTRIEVE], [CSA]
- Jehn M, Clark J M, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004; 27: 2422–2428, [INFOTRIEVE], [CSA]
- Afzali B, Goldsmith D J. Intravenous iron therapy in renal failure: Friend and foe?. J Nephrol 2004; 17: 487–495, [INFOTRIEVE], [CSA]
- Chicharro J L, Hoyos J, Gomez-Gallego F, Villa J G, Bandres F, Celaya P, Jimenez F, Alonso J M, Cordova A, Lucia A. Mutations in the hereditary haemochromatosis gene HFE in professional endurance athletes. Br J Sports Med 2004; 38: 418–421, [INFOTRIEVE], [CROSSREF], [CSA]
- Beutler E, Hoffbrand A V, Cook J D. Iron deficiency and overload. Hematology (Am Soc Hematol Educ Program) 2003; 40–61, [CSA]
- Xi L, Taher M, Yin C, Salloum F, Kukreja R C. Cobalt chloride induces delayed cardiac preconditioning in mice through selective activation of HIF-1α and AP-1 and iNOS signaling. Am J Physiol Heart Circ Physiol 2004; 287: H2369–H2375, [INFOTRIEVE], [CROSSREF], [CSA]
- Dery M A, Michaud M D, Richard D E. Hypoxia-inducible factor-1: Regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 2005; 37: 535–540, [INFOTRIEVE], [CROSSREF], [CSA]
- Holly R G. Studies on iron and cobalt metabolism. JAMA 1955; 158: 1349–1352, [CSA]
- Lippi G, Franchini M, Guidi G C. Cobalt chloride administration in athletes: A new perspective in blood doping?. Br J Sports Med 2005; 39: 872–873, [INFOTRIEVE], [CROSSREF], [CSA]
- Ayala-Fierro F, Firriolo J M, Carter D E. Disposition, toxicity, and intestinal absorption of cobaltous chloride in male Fischer 344 rats. J Toxicol Environ Health A 1999; 56: 571–591, [INFOTRIEVE], [CROSSREF], [CSA]
- Pourahmad J, O'Brien P J, Jokar F, Daraei B. Carcinogenic metal induced sites of reactive oxygen species formation in hepatocytes. Toxicol In Vitro 2003; 17: 803–810, [INFOTRIEVE], [CROSSREF], [CSA]
- Barceloux D G. Cobalt. Toxicol Clin Toxicol 1999; 37: 201–216, [CROSSREF], [CSA]
- Lippi G, Guidi G. New scenarios in antidoping research. Clin Chem 2003; 49: 2106–2107, [INFOTRIEVE], [CROSSREF], [CSA]
- Lippi G, Guidi G C. Gene manipulation and improvement of athletic performances: New strategies in blood doping. Br J Sports Med 2004; 38: 641, [INFOTRIEVE], [CROSSREF], [CSA]
- Unal M, Ozer Unal D. Gene doping in sports. Sports Med 2004; 34: 357–362, [INFOTRIEVE], [CROSSREF], [CSA]
- Pincock S. Feature: Gene doping. Lancet 2005; 366(Suppl 1)S18–S19, [INFOTRIEVE], [CROSSREF], [CSA]
- Azzazy H M, Mansour M M, Christenson R H. Doping in the recombinant era: Strategies and counterstrategies. Clin Biochem 2005; 38: 959–965, [INFOTRIEVE], [CROSSREF], [CSA]
- Bohl D, Bosch A, Cardona A, Salvetti A, Heard J M. Improvement of erythropoiesis in beta-thalassemic mice by continuous erythropoietin delivery from muscle. Blood 2000; 95: 2793–2798, [INFOTRIEVE], [CSA]
- Gao G, Lebherz C, Weiner D J, Grant R, Calcedo R, McCullough B, Bagg A, Zhang Y, Wilson J M. Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 2004; 103: 3300–3302, [INFOTRIEVE], [CROSSREF], [CSA]
- Walker M C, Mandell T C, Crawford P C, Simon G G, Cahill K S, Fernandes P J, MacLeod J N, Byrne B J, Levy J K. Expression of erythropoietin in cats treated with a recombinant adeno-associated viral vector. Am J Vet Res 2005; 66: 450–456, [INFOTRIEVE], [CROSSREF], [CSA]
- Rivera V M, Gao G P, Grant R L, Schnell M A, Zoltick P W, Rozamus L W, Clackson T, Wilson J M. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 2005; 105: 1424–1430, [INFOTRIEVE], [CROSSREF], [CSA]
- Lippin Y, Dranitzki-Elhalel M, Brill-Almon E. Human erythropoietin gene therapy for patients with chronic renal failure. Blood 2005; 106: 2280–2286, [INFOTRIEVE], [CROSSREF], [CSA]
- Williams D A, Baum C. Gene therapy—New challenges ahead. Science 2003; 302: 400–401, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kimmelman J. Recent developments in gene transfer: Risk and ethics. BMJ 2005; 330: 79–82, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Verhoeyen E, Cosset F L. Inadvertent autoimmunity in EPO gene transfer. Blood 2004; 103: 3248–3249, [CROSSREF], [CSA]
- Emanuel E J, Wendler D, Grady C. What makes clinical research ethical?. JAMA 2000; 283: 2701–2711, [INFOTRIEVE], [CROSSREF], [CSA]
- Diamanti-Kandarakis E, Konstantinopoulos P A, Papailiou J, Kandarakis S A, Andreopoulos A, Sykiotis G P. Erythropoietin abuse and erythropoietin gene doping: Detection strategies in the genomic era. Sports Med 2005; 35: 831–840, [INFOTRIEVE], [CROSSREF], [CSA]
- Rieu M. The fight against doping: Today and tomorrow. Bull Acad Natl Med 2004; 188: 955–971, [INFOTRIEVE], [CSA]
- Schmidt M, Zickler P, Hoffmann G, Haas S, Wissler M, Muessig A, Tisdale J F, Kuramoto K, Andrews R G, Wu T, Kiem H P, Dunbar C E, von Kalle C. Polyclonal long-term repopulating stem cell clones in a primate model. Blood 2002; 100: 2737–2743, [INFOTRIEVE], [CROSSREF], [CSA]